Postgraduate program aims to turn geroscience, biomarkers and emerging technologies into evidence-based healthspan medicine for physicians.
Longevity medicine has never been short of theory; what it has lacked is a settled bedside manner. Tel Aviv University hopes to supply one. Its new advanced postgraduate course asks physicians to carry geroscience, deep phenotyping and personalized prevention out of the lecture theater and into the consulting room – with the evidence kept firmly in view.
Directed by Professors Tzipi Strauss and Evelyne Bischof, Healthy Longevity Science & Healthspan Medicine will run across 10 fortnightly sessions between November 2026 and March 2027. It is open to physicians of any specialty, and to dentists. The emphasis is clinical by design. Mechanisms of aging are covered, naturally, but the course is built around what comes after them: assessing patients, making sense of increasingly dense biological data and turning it into an individualized healthspan plan.
The course is run in collaboration with the Sheba Longevity Center at Sheba Medical Center, which Strauss founded and directs and where Bischof is medical director. Its curriculum draws on more than three years of hands-on experience from what the organizers describe as the first dedicated healthy longevity medicine department in a public academic hospital – experience rather than theory being, in a field this young, the scarcer commodity.
Taught in English over Zoom, the course concludes with a final assessment and a Tel Aviv University certificate of attendance.
Speaking to Longevity.Technology, course codirector Evelyne Bischof emphasized the need to bridge scientific potential with clinical reality:
“The central challenge in longevity medicine is not simply understanding the rapidly evolving science, but knowing what can responsibly be translated into clinical practice today. This course was strategically developed with exactly this goal: to provide physicians with an evidence-based framework to distinguish established clinical approaches from promising interventions that still require validation, while giving them practical tools to implement healthspan assessment and personalized interventions in everyday clinical practice.”
Longevity.Technology: As longevity medicine moves closer to clinical practice, educating physicians in geroscience is only part of the challenge. The harder task is translating a rapidly expanding toolkit – from aging clocks and multi-omics to AI and deep phenotyping – into decisions that are genuinely useful for patients.
The distinction between what can be measured and what is clinically actionable is critical. More data does not automatically mean better medicine, particularly in areas where evidence is still emerging. Courses such as this therefore have an important role to play not only in teaching physicians what longevity science makes possible, but also where the evidence currently draws the line. That ability to navigate uncertainty – knowing when to intervene, when to monitor and when the science simply isn’t there yet – will be an important part of establishing longevity medicine as a credible clinical discipline.
From hallmarks to healthspan
Biology comes first. The opening sessions set out the mechanisms of aging and the case for geroscience, then move to the more contested business of measurement: epigenetic, proteomic, metabolomic and transcriptomic clocks, genomics and the integration of multi-omics data – territory in which the syllabus pointedly asks what is clinically actionable. From there the course works through the body system by system. Heart and vasculature, diet and metabolism (repurposed drugs included), muscle and bone, sleep, hormones and the brain each claim a session, while the immune system and microbiome share one; it amounts to a tour of the places where aging does its slow, cumulative work.
Technology forms the final layer, with AI and digital health considered in the context of integrating disparate measurements into a continuous picture of health. Case-based learning runs through the program and culminates in participants producing an evidence-based assessment, healthspan plan and responsible intervention proposal.
The faculty also reaches beyond Tel Aviv. International contributors include Mayo Clinic’s Professor Sara Bonnes and Albert Einstein College of Medicine’s Professor Nir Barzilai, alongside Professor David Dodick, Professor Lorenzo Dagna of San Raffaele in Milan and Stanford’s Professor David Furman. Their expertise spans metabolism, nutrition, neuro-longevity, immunoaging and advanced aging biomarkers.
Building the clinical infrastructure
The course arrives as the clinical longevity sector is beginning to grapple more seriously with training, standards and shared terminology. Longevity Clinics World, Longevity.Technology’s platform for the global clinic ecosystem, has already expanded into education through its Education and Training Marketplace, developed to bring greater structure to a training landscape that remains fragmented.
That question of training is closely connected to what happens inside clinics themselves. As longevity services extend from established preventive medicine into biological age assessment, multi-omics and newer interventions, clinical credibility depends increasingly on practitioners being able to separate useful signal from expensive noise – and to explain the difference to patients.
Learning to draw the line
New tests, targets and technologies will keep arriving; they generally do, and seldom without an invoice. Judgment is harder to come by. A physician who can look at an aging clock, ask what exactly it is counting and decide whether the answer should change anything on Monday morning is worth rather more to the field than another assay. Tel Aviv is betting that such skepticism can be taught. It is a sensible wager; in a discipline still finding its edges, knowing where the evidence stops may turn out to be the most clinical skill of all.
